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Abstract
Up-regulated sirtuin 1 (SIRT1), an NAD+-dependent class III histone deacetylase, deacetylates p53 and inhibits its
transcriptional activity, leading to cell survival. SIRT1 overexpression has been reported to predict poor survival in some
malignancies, including gastric cancer. However, the antitumor effect of SIRT1 inhibition remains elusive in gastric cancer.
Here, we investigated the antitumor mechanisms of a sirtuin inhibitor, tenovin-6, in seven human gastric cancer cell lines
(four cell lines with wild-type TP53, two with mutant-type TP53, and one with null TP53). Interestingly, tenovin-6 induced
apoptosis in all cell lines, not only those with wild-type TP53, but also mutant-type and null versions, accompanied by up-
regulation of death receptor 5 (DR5). In the KatoIII cell line (TP53-null), DR5 silencing markedly attenuated tenovin-6-induced
apoptosis, suggesting that the pivotal mechanism behind its antitumor effects is based on activation of the death receptor
signal pathway. Although endoplasmic reticulum stress caused by sirtuin inhibitors was reported to induce DR5 up-
regulation in other cancer cell lines, we could not find marked activation of its related molecules, such as ATF6, PERK, and
CHOP, in gastric cancer cells treated with tenovin-6. Tenovin-6 in combination with docetaxel or SN-38 exerted a slight to
moderate synergistic cytotoxicity against gastric cancer cells. In conclusion, tenovin-6 has potent antitumor activity against
human gastric cancer cells via DR5 up-regulation. Our results should be helpful for the future clinical development of sirtuin
inhibitors.
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Introduction
Gastric cancer is one of the major causes of cancer death
around the world [1,2]. Although various chemotherapies for
advanced gastric cancer have been developed, the prognosis is still
poor and novel anticancer drugs for gastric cancer are needed.
Gastric cancer is a biologically and genetically heterogeneous
cancer involving numerous genetic mutations and epigenetic
alternations [3]. Among these, abnormalities of the TP53 tumor
suppressor gene play an important role in tumorigenesis [4,5].
Approximately 30% of patients with gastric cancer have TP53
mutation [6]. Even in cancer cells with wild-type (wt) TP53, it has
been reported that the function of TP53 is suppressed by negative
regulation including ubiquitination, methylation, and deacetyla-
tion [7,8]. In this context, it would be a promising strategy to
assume that inhibition of these negative regulators results in
enhancement of antitumor effects through activation of p53 in wt
TP53 cancers. Murine double minute 2 (MDM2) is a major
physiological antagonist of p53 [7]. We previously reported that an
MDM2 inhibitor, nutlin-3, demonstrated potent antitumor effects
against gastric cancer cells through activation of the p53 pathway
[9].
Sirtuin 1 (SIRT1), an NAD+-dependent histone deacetylase
(HDAC), has a variety of functions involved in chromatin
silencing, longevity, and genomic stability. It is found in the
nucleus and acts as a sensor of cell metabolic status in survival and
senescence under genotoxic and oxidative stress [10,11]. Besides
histone deacetylation, these functions partly depend on the
deacetylation of various non-histone proteins that include tran-
scriptional factors: p53, forkhead box (FOXO) family proteins,
nuclear factor kB, c-MYC, N-MYC, E2F1, and hypoxia-inducible
transcription factors (HIF) 1a/2a; chromatin-related enzymes:
histone acetyltransferase, p300, DNA-dependent kinase subunit
Ku80, and TIP60; DNA repair elements: Ku70, RAD51, and
NBS1; and cell-signaling factors: STAT3, b-catenin, and Smad7
[11–13]. SIRT1 physiologically interacts with p53 and attenuates
its functions through deacetylation at its C-terminal Lys382
residue [12]. Overexpression of SIRT1 was found in many
cancers, such as stomach and colon [10,14], and reported to
function as a tumor promoter. SIRT2 is one of the cytoplasmic
NAD+-dependent histone deacetylases and deacetylates histone
H3 lysine 56 (H3K56) and a-tubulin. It also shares non-histone
substrates of FOXO1, FOXO3, and p53 with SIRT1 [11].
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However, the exact role of SIRT2 remains elusive in cancer
biology.
Against this background, we investigated whether tenovin-6, a
small-molecule compound that inhibits SIRT1 and SIRT2
functions [15,16], exerted antitumor effects through activation of
the p53 pathway in gastric cancer cells. Recently, it has been
reported that SIRT inhibitors up-regulated the death receptor 5
(DR5), a member of the tumor necrosis factor receptor family, in
some cancers [17,18]. We additionally studied the involvement of
this receptor in the antitumor activity of tenovin-6 for gastric
cancer. Furthermore, we examined the synergism of tenovin-6
with conventional cytotoxic drugs for the future clinical develop-
ment in gastric cancer.
Materials and Methods
Cell lines
Seven gastric cancer cell lines were used: four cell lines with wt
TP53 (MKN-45, NUGC-4, STKM-2, SNU-1), two cell lines with
mutant-type (mt) TP53 (NUGC-3, STKM-1), and one cell line
with null TP53 (KatoIII) [19–21]. Cell lines with wt TP53 (MCF-
7 breast cancer, HEK293 human embryonic kidney cells) and
MRC-5 normal human fibroblasts were included as controls in
this study. MKN-45, NUGC-4, KatoIII, and MRC-5 cell lines
were obtained from RIKEN BRC Cell Bank (Tsukuba, Japan).
SNU-1 and MCF-7 cell lines were purchased from the American
Type Culture Collection (Rockville, MD). NUGC-3 and HEK293
cell lines were obtained from Health Science Research Resources
Bank (Osaka, Japan). STKM-1 and STKM-2 cell lines were kindly
provided by Dr. Shunsuke Yanoma (Yokohama City University,
School of Medicine, Japan).
Chemicals
Tenovin-6 was purchased from Cayman Chemical Company
(Ann Arbor, MI). Docetaxel, SN-38, cisplatin, 5-fluorouracil (5-
FU), doxorubicin and thapsigargin were obtained from Wako
(Osaka, Japan). They were dissolved in dimethyl sulfoxide
(DMSO) at a concentration of 20 mM and aliquots were stored
at -20 uC. Stock solutions were diluted to the desired final
concentrations with growth medium prior to use.
Antibodies and Western blot analysis
SDS-polyaclylamidegel electrophoresis and Western blotting
were performed as previously described [22]. The primary and
secondary antibodies used were as follows. Rabbit polyclonal
antibodies against SIRT1 (D739), acetylated (Ac)-p53 (Lys382),
phosphorylated (Phospho)-p53 (Ser15), Bcl-2, Ac-a-tubulin
(Lys40), death receptor 5 (DR5), Fas-associated death domain
(FADD), cleaved poly(ADP)-ribose polymerase (PARP) (Asp214),
and mouse monoclonal antibodies against p21Waf/Cip1 (DCS60),
histone H3 (96C10), b-actin (8H10D10), a -tubulin (DM1A) and
C/EBP homologue protein (CHOP) (L63F7), and rabbit mono-
clonal antibodies against TRAIL (C92B9), caspase-3 (8G10),
inositol-requiring enzyme (IRE) 1a (14C10), and phospho-RNA-
dependent protein kinase-like endoplasmic reticulum kinase
(PERK) (16F8) were obtained from Cell Signaling Technology
(Danvers, MA). Mouse monoclonal antibody to p53 (BP53-12) was
purchased from Cell Science (Canton, MA), anti-SIRT2 (4B11)
monoclonal antibody was from Sigma-Aldrich. (St. Louis, MO),
and anti-activating transcription factor 6 (ATF6) monoclonal
antibody (70B1413.1) was from Enzo Life Science (Farmingdale,
NY). Rabbit polyclonal antibody to Ac-histone H3 (Lys18) was
from Merck Millipore (Billerica, MA). Both horseradish peroxi-
dase (HRP)-conjugated anti-mouse IgG sheep and anti-rabbit IgG
donkey sera were from GE Healthcare (Buckinghamshire, UK).
Antibody binding was detected using an ECL Prime Western
Blotting Detection System (GE Healthcare), in accordance with
the manufacturer’s protocol. The signal intensity was quantified
using Ez-capture II chemiluminescence imaging system (Atto,
Tokyo, Japan).
Real-time quantitative PCR for analysis of SIRT1 and SIRT2
gene expression
RNA samples were extracted from cell lysate using a High Pure
RNA Isolation kit (Roche Diagnostics, Mannheim, Germany), in
accordance with the manufacturer’s instructions. After the
genomic DNA was removed by DNase, cDNA was prepared
using a High Capacity RNA-to-cDNA kit (Life Technologies
Corp., Carlsbad, CA). Real-time quantitative PCR was performed
using an Applied Biosystems 7500 Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA). Primers and TaqMan
probe for SIRT1 and SIRT2 were obtained from Applied
Biosystems (Assay ID: Hs01009005 and Hs00247263, respective-
ly), and those for 18S ribosomal RNA (18S rRNA) designed and
synthesized by Sigma-Aldrich were as follows: 59-AACCCGTT-
GAACCCCATTCG (forward primer), 59-CGGGCGGTGTGT-
ACAAAGG (reverse primer), 59-AACGCAAGCTTATGACCC-
GCACTTACTGG (probe). Reactions were performed in triplicate
under standard thermocycling conditions using 30 ng of cDNA,
900 nM primers, 250 nM probes, and a Taqman Gene Expression
Master Mix (Applied Biosystems), in accordance with the
manufacturer’s protocol.
RNAs extracted from cells were analyzed for the relative
amounts of the target gene (SIRT1, SIRT2) and the reference
gene (18S rRNA) by quantitative real-time PCR.
WST-8 cell viability assays
WST-8 colorimetric assays were performed using a Cell
Counting Kit-8 (Dojin Laboratories, Kumamoto, Japan), in
accordance with the manufacturer’s protocol. Cells were seeded
into 96-well plates at a density of 56103 cells per well with 100 ml
of culture medium for 24 h, treated with tenovin-6 for 72 h,
incubated in the presence of WST-8, and then analyzed with an
iMark microplate reader (Bio-Rad, Hercules, CA).
Analysis of apoptosis by flow cytometry
Cells were seeded in 60-mm dishes at a density of 56105 per
dish. After incubation with tenovin-6 (10 mM) or an equivalent
amount of DMSO for 72 h, cells were gently lifted with Accutase
(US Biotechnologies, Parker Ford, PA) at room temperature for
10 min. The cells were then washed once with phosphate buffered
saline. Apoptotic cells were detected by double staining with
propidium iodide (PI) and fluorescein isothiocyanate (FITC)-
labeled annexin V using an Annexin V-FITC Apoptosis Detection
Kit (Beckman Coulter, Brea, CA), in accordance with the
manufacturer’s protocol. Flow cytometric analysis was then
performed with a FACS Calibur flow cytometer (BD Biosciences,
Franklin Lakes, NJ) and CELLQuest software (BD Biosciences).
siRNA targeting DR5
siRNA targeting DR5 was designed using siDirect software
(http://sidirect2.rnai.jp/), as reported previously [22]. siRNA
transfection was carried out using Lipofectamine RNAiMAX
(Invitrogen, Carlsbad, CA), in accordance with the manufacturer’s
instructions. Control siRNA was an artificial sequence designed to
have the least homology to human and mouse genes. The sense
and antisense strands of siRNA used in this study were as follows:
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DR5, 5’-CCGUUUGUGCGUACUUUGAGA-3’ (sense), 5’-UC-
AAAGUACGCACAAACGGAA-3’ (antisense); control siRNA,
5’-CCGUACUAGCCAUUAUGCGUC-3’ (sense), 5’-CGCAUA-
AUGGCUAGUACGGGU-3’ (antisense).
For analysis of the effects of siRNA on cell growth and viability,
cells were plated at a low density (16103 cells per well) in 96-well
plates containing 100 ml of RPMI1640 medium with 10% fetal calf
serum (Sigma-Aldrich). The viability of transfected cells was
assessed 72 and 120 h after transfection by WST-8 assay.
Combination index
To determine whether tenovin-6 can enhance the antitumor
effects of conventional chemotherapeutic agents, we used a
combination index (CI) and an isobologram calculated using
CalcuSyn software (Cambridge, UK), in accordance with the
Chou and Talalay median effect principle [23]. In this analysis, CI
.1.3 indicates antagonism; CI = 1.1–1.3 moderate antagonism;
CI = 0.9–1.1 additive effect; CI = 0.8–0.9 slight synergism; CI
= 0.6–0.8 moderate synergism; CI = 0.4–0.6 synergism; and CI
= 0.2–0.4 strong synergism.
Statistical analysis
All experiments were performed in triplicate and were repeated
at least three times. All data are expressed as mean 6 standard
deviation (SD). The significance of differences was determined by
Student’s t-test and Dunnett’s test. p-values ,0.05 were consid-
ered significant.
Results
Expression of SIRT1, SIRT2, and acetylated (Ac)-p53 in
gastric cancer cell lines
First, we examined the expression levels of SIRT1, SIRT2, and
Ac-p53 in seven gastric cancer cell lines. We used HEK293 cells
for the positive control of SIRT1/2, and MCF-7 cells treated with
doxorubicin for the positive control of Ac-p53 [24]. All gastric
cancer cell lines except for NUGC-4 and STKM-1 cells expressed
high levels of SIRT1 protein, and SIRT2 expression levels were
low in all cell lines except for MKN-45 cells (Figure 1A). Ac-p53
expression levels were very low in all gastric cancer cell lines with
wt TP53.
We analyzed the gene expression of SIRT1 and SIRT2 by real-
time quantitative PCR. MKN-45 cells exhibited SIRT1 gene
expression that was about 2.5 fold higher than that in fibroblasts,
but other gastric cancer cell lines did not (Figure 1B). In NUGC-4
cells, the level of gene expression of SIRT1 was low, as was SIRT1
protein. MKN-45 cells showed slightly high SIRT2 gene
expression, while other cell lines showed rather low expression
levels.
Tenovin-6 inhibited growth of gastric cancer cells
In order to confirm tenovin-6 activity, we studied whether
tenovin-6 affected the acetylation of histone H3 and a-tubulin.
Tenovin-6 increased the acetylation of histone in three (MKN-45,
NUGC-4, and KatoIII) of the four gastric cancer cell lines tested,
indicating the inhibition of SIRT1 deacetylation activity
(Figure 2A). Ac-a-tubulin increased only in one cell line (MKN-
45) treated with tenovin-6, hence inhibition of SIRT2 deacetyla-
tion activity could not be definitely shown in gastric cancer cells.
Next, we evaluated the potential anti-tumor effect of tenovin-6
against gastric cancer cells. Each gastric cancer cell line was
cultured in the presence of tenovin-6 (0.2, 1, 5, 10, 20, and 50 mM)
for three days. Dose-dependent growth inhibition was observed in
all cell lines, not only those with wt TP53 but also mt and null
versions (Figure 2B). Their IC50 values ranged from 2.34 to
4.28 mM. In addition, WST-8 assay was performed in the human
fibroblast cell line MRC-5 (IC50: 6.09 mM) to compare the toxicity
of tenovin-6 to gastric cancer cell lines. The viability of NUGC-4
cells treated with tenovin-6 was significantly lower than that of
MRC-5 cells, as shown in Figure 2C.
Tenovin-6 induced apoptotic cell death in gastric cancer
cells
As shown in Figure 3A and S1, tenovin-6 treatment increased
the expression of p53 and p21 in wt TP53 cells (MKN45 and
NUGC-4). Up-regulation of Ac-p53 was shown in MKN-45 cells,
but not in NUGC-4 cells. Increased p21 expression was also
observed in mt TP53 cells (NUGC-3). By contrast, bcl-2
expression did not change in almost all four gastric cancer cell
lines. Increases of DR5 and cleaved PARP expression were
observed in all cell lines tested. The levels of expression of TRAIL,
which function as a ligand in coupling death signaling, was slightly
increased in all cell lines, although the expression of FADD, an
important adaptor, was not affected by tenovin-6.
We examined whether tenovin-6 decreased the viability of
gastric cancer cells through the induction of apoptotic cell death.
Cancer cells were exposed to it at a concentration of 10 mM or an
equivalent amount of control vehicle (DMSO) for 72 h, and then
stained with FITC-annexin V and PI. They were analyzed by flow
cytometry: cells negative for both annexin V and PI were
considered to be non-apoptotic, cells positive for annexin V only
were considered to be early apoptotic, and cells positive for both
annexin V and PI were considered to be late apoptotic or necrotic.
Exposure of MKN-45 cells to tenovin-6 increased the fractions of
early and late phases of apoptosis from 2.8% to 52.1% and from
1.8% to 18.5%, respectively (Figure 3B). Similar increases in the
populations in early and late phases of apoptosis were observed in
other cell lines (NUGC-4, NUGC-3, and KatoIII). Tenovin-6
induced apoptosis in all cell lines tested, regardless of TP53 status.
Effect of DR5 knockdown on tenovin-6-induced
apoptosis
Next, to verify whether DR5 silencing affected tenovin-6-
induced apoptosis, cell viability and apoptotic rate were analyzed
by WST-8 assay and flow cytometry, respectively, in TP53-null
KatoIII cells. Inhibition of DR5 expression by specific siRNA
(Figure 4A) significantly reduced tenovin-6-induced cell death and
apoptosis in KatoIII cells (Figure 4B and 4C). We used three
different siRNAs in our preliminary experiment, and we got the
similar results with any siRNAs.
We investigated activation of the endoplasmic reticulum (ER)
stress pathway, which is linked to DR5 up-regulation, as previously
reported [17]. CHOP is one of the most potent inducer of DR5
and upstream of apoptosis, and frequently released during the ER
stress. As shown in Figure 5A and 5B, although CHOP was
marginally up-regulated by tenovin-6 treatment in all four gastric
cancer cell lines, the increased levels were significantly lower than
that in control cells treated with thapsigargin, which is a selective
inhibitor of sarcoplasmic/endoplasmic reticulum Ca2+ - ATPases
and widely used as a cellular ER stressor [25,26]. On the other
hands, IRE1, which is an ER stress sensor and located at upstream
of CHOP, was slightly up-regulated by tenovin-6 treatment in all
cell lines, but not phosphorylated PERK and ATF6. [27,28]. It
seemed unlikely that tenovin-6 caused ER stress leading to DR5
induction in our gastric cancer cells.
Antitumor Effects of Tenovin-6 in Gastric Cancer
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Antitumor effect of tenovin-6 in combination with
chemotherapeutic agents
Finally, we examined whether tenovin-6 enhanced the antitu-
mor effects of chemotherapeutic agents including docetaxel, SN-
38, cisplatin, and 5-FU, in gastric cancer cell lines. Four cell lines
with wt TP53 (MKN-45, NUGC-4), mt TP53 (NUGC-3), and
null TP53 (KatoIII) were treated with these agents alone or in
combination with two doses (2 and 5 mM) of tenovin-6. The
concentrations were 0.25 nM docetaxel, 1 nM SN-38, 0.5 or
1 mM cisplatin, and 0.25 mM 5-FU. As shown in Table 1 (and
Figure S2), docetaxel and SN-38 showed a slight to moderate
synergistic effect on tenovin-6 treatment in three cell lines, and
cisplatin with tenovin-6 showed a moderate synergistic effect in
two cell lines, whereas 5-FU in combination with tenovin-6
showed a lower effect than the other agents. We examined the
expressions of DR5 after administration of tenovin-6 with
chemotherapeutic agents. DR5 up-regulation by tenovin-6 was
enhanced with a combination of docetaxel in MKN-45 cells
(Figure S3).
Discussion
We demonstrated that tenovin-6 showed potent antitumor
activity accompanied by apoptotic cell death in human gastric
cancer cells with wt TP53 as well as those with mt TP53. Several
specific inhibitors of sirtuins, such as sirtinol, suramin, salermide,
and thiobarbiturates, were reported to inhibit cell growth in
various types of cancer [29]. Most researchers described the
antitumor effects of sirtuin inhibitors in cell lines with wt TP53
[15,29-31], and attributed these to the activation of apoptosis
through acetylation of p53. Meanwhile, several reports were
published in recent years that showed the antitumor activities of
sirtuin inhibitors in cell lines with mt TP53 through p53-
independent pathways [17,18]. We showed that DR5 knockdown
attenuated the antitumor effects of tenovin-6 in TP53-null gastric
cancer cells. Activation of the death receptor signal pathway via
up-regulation of DR5 plays a pivotal role in tenovin-6-induced cell
death, as mentioned in other reports on sirtuin inhibitors.
It has been reported that salermide enhanced DR5 expression
and induced apoptosis in human non-small-cell lung cancer cells
carrying mt TP53 [17]. In that report, simultaneous silencing of
SIRT1 and SIRT2 as well as salermide up-regulated DR5,
accompanied by the up-regulation of ER stress-related proteins,
such as ATF4 and CHOP. These results suggested that ER stress
was involved in this DR5 induction. We speculated that tenovin-6
also led to an increase of DR5 expression via activation of ER
stress mediated by PERK, IRE1, ATF6, and CHOP. However,
contrary to expectations, the signal pathway of ER stress activated
by tenovin-6 was not obviously detected. Nevertheless, there was
clear evidence that DR5 was induced by tenovin-6. There are
other pathways of CHOP-mediated DR5 up-regulation: reactive
oxygen species (ROS), the c-Jun NH2-terminal kinase (JNK)
pathway, the p38 mitogen-activated protein kinase pathway, and
so on [32–38]. However, we did not examine these pathways here
because we could not identify CHOP activation in our study. Our
results suggest that other p53- and CHOP-independent pathways
participate in tenovin-6-induced DR5 expression in gastric cancer
cells.
We demonstrated that tenovin-6 induced apoptotic cell death
through activation of the DR5 pathway. However, p53 and
Figure 1. Expression of SIRT1, SIRT2, and acetylated (Ac)-p53 in gastric cancer cells. A: The expression of SIRT1, SIRT2, p53, Ac-p53, and
phospho-53 in seven gastric cancer cell lines and MRC-5 fibroblasts was examined by Western blotting. Semi-quantitation of Western blotting
densitometry involved normalization to b-actin levels. MCF-7*: MCF-7 cells treated with doxorubicin (1 mM, 24 h). B: Expression of SIRT1 mRNA and
SIRT2 mRNA in gastric cancer cells. Levels of SIRT1 mRNA and SIRT2 mRNA were determined in gastric cancer cells and MRC-5 fibroblasts by
quantitative real-time PCR and normalized to the level of 18S rRNA. mRNA levels are shown relative to those of MRC-5 fibroblasts.
doi:10.1371/journal.pone.0102831.g001
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CHOP pathways seemed unlikely to be involved in this DR5
induction, and the mechanism of DR5 up-regulation remains
unclear. We have, recently, investigated antitumor effects of
tenovin-6 in several colon cancer cell lines, and found its potent
antitumor activity against most of them with up-regulation of DR5
as well [39]. However in CaCo2 colon cancer cells (mt TP53),
apoptotic cell death by tenovin-6 was less evident and DR5
expression was not strongly up-regulated. CaCo2 cell have been
reported to express high level of heat shock proteins known as a
suppressor of DR5 [40-43]. This relation should be studied further
in future. SIRT1 can deacetylate histone H4 lysine 16 (H4K16) as
well as H3K9, H3K14, and H1K26, which are closely related to
Figure 2. Tenovin-6-induced acetylation of H3 and a-tubulin, and antitumor effects in gastric cancer cells. A: Gastric cancer cells were
cultured with tenovin-6 (10 mM) for various time periods and analyzed for the levels of SIRT1, SIRT2, Ac-H3, and Ac-a-tubulin by Western blotting. B:
Tenovin-6 inhibited the growth of gastric cancer cells regardless of TP53 status. All experiments were assessed by WST-8 assay and carried out in
triplicate. Results are expressed as the mean 6 SD. C: WST-8 assay was performed in MRC-5 cells to compare the toxicity of tenovin-6 to cancer cell
lines. The growth inhibition of tenovin-6 in NUGC-4 cells was significantly higher than that in MRC-5 cells. The significance of differences was
evaluated using Student’s t-test.
doi:10.1371/journal.pone.0102831.g002
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Figure 3. Induction of apoptotic cell death by tenovin-6 in gastric cancer cells. A: Time-course analysis of the expression of p53, its
downstream molecule p21Waf/Cip1, and apoptosis-related molecules in gastric cancer cells treated with tenovin-6 (10 mM). Relative intensity of the
proteins’ expression is shown in Figure S1. Tenovin-6 induced the expression of Ac-p53 and p21Waf/Cip1, but not Bcl-2. DR5 expression was strongly
induced by tenovin-6. TRAIL, and cleaved PARP were slightly increased, but FADD expression was not affected. A doublet of DR5 shows its precursor
(upper band) and mature isoforms (lower band). B: Four cell lines were treated with tenovin-6 (10 mM) or a vehicle control for 72 h, double-stained
with FITC-annexin V and PI, and analyzed by flow cytometry. The statistical significance of differences between groups was evaluated using Student’s
t-test. * p,0.01; ** p,0.05.
doi:10.1371/journal.pone.0102831.g003
Antitumor Effects of Tenovin-6 in Gastric Cancer
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gene silencing [11]. In addition, it has many corresponding non-
histone substrates: transcriptional factors, DNA repair machinery
elements, nuclear receptors, histone-modifying enzymes, and cell
signaling molecules, as described elsewhere [11–13]. These
numerous and complicated associations of SIRT1 activity are
involved in various biological functions, such as regulation of gene
expression and DNA damage repair. Cancer cells tend to require
these functions of SIRT1 in order to survive, proliferate, and
repair catastrophic genomic damage. Recent studies have
identified the ability of tenovin-6 to induce differentiation and
inhibit autophagy as part of its anti-neoplastic effects in leukemia
cells [44,45]. It may depend on cancer cell behavior how tenovin-6
affects neoplastic activity. Further studies are needed to clarify the
link between the tenovin-6-mediated death pathway and the
complex roles of SIRT1.
We examined the effects of combining docetaxel, SN-38,
cisplatin, and 5-FU with tenovin-6 because they have been widely
used for the treatment of patients with advanced gastric cancer
[46,47]. Slight to moderate synergistic effects of docetaxel and SN-
38 with tenovin-6 in the gastric cancer cell lines, regardless of
TP53 status, were found.
Although treatments involving combinations of docetaxel and
sirtuin inhibitors have not been reported, combinations of
docetaxel and other HDAC inhibitors such as trichostatin A and
suberoylanilide hydroxamic acid (SAHA) have been reported to
have synergistic effects related to caspase activation or tubulin
acetylation in several cancer cell lines [48–50]. In our study, it
remains unclear if the tubulin acetylation by tenovin-6 always
affected the antitumor effect, because the tubulin acetylation was
shown only in one cell line. SN-38 (the active form of irinotecan) is
a DNA topoisomerase I inhibitor that acts only during the S phase
and interferes with DNA replication and cell division [51,52].
HDAC inhibitors induce acetylation of histones and loosen the
chromatin structure, whereby topoisomerase inhibitor may more
easily access DNA, facilitating DNA damage [51,53]. In addition,
a remarkable increase of ROS generation has been reported in
small-cell lung cancer cells upon simultaneous exposure to SAHA
and topotecan (a derivative of camptothecin) [51]. The increased
potency of treatment combining tenovin-6 and SN-38 might be
attributable to cooperative regulation of the DNA damage
response.
The advantage of combined therapy with tenovin-6 and
cisplatin or 5-FU was less than that with the other agents in
gastric cancer cells, although several reports have demonstrated
the enhancement of apoptosis by combined treatment with
cisplatin or 5-FU and other HDAC inhibitors in other tumors
[54–57].
Figure 4. Effects of DR5 knockdown on cell survival and apoptosis in TP53-null KatoIII cells. A: KatoIII cells were transfected with 1 nM
siRNA control or siRNA against DR5 mRNA. Forty-eight hours after transfection, the cells were treated with 5 mM tenovin-6 for 24 h. Western blotting
showed the down-regulation of DR5 by siRNA transfection. A doublet of DR5 shows its precursor (upper band) and mature isoforms (lower band). B:
Cells were transfected with 1nM siRNA control or DR5 siRNA for 48 h, treated with 0.2, 1, and 5 mM tenovin-6 for 72 h and then subjected to cell
viability measurements by WST-8 assay. The statistical significance of differences between groups was evaluated using Student’s t-test. * p,0.01; **
p,0.05. C: The effect of DR5 knockdown on tenovin-6 induced apoptosis was analyzed by flow cytometry using PI staining. The results are expressed
as the mean 6 SD. The statistical significance of differences between groups was evaluated using Student’s t-test.
doi:10.1371/journal.pone.0102831.g004
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Figure 5. Expression of proteins associated with ER stress in gastric cancer cell lines treated with tenovin-6. A: Expression of proteins
associated with ER stress in gastric cancer cell lines before and after treatment with 10 mM tenovin-6. Thapsigargin at 3 mM was administered to
HEK293 cells as a control. A doublet of DR5 shows its precursor and mature isoforms. B: Relative intensity of expression of CHOP in cell lines tested is
shown. The statistical significance of differences between groups was evaluated using Dunnett’s test.
doi:10.1371/journal.pone.0102831.g005
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Regarding the toxicity evaluation of tenovin-6, we used a
fibroblast cell line as the alternative non-tumorigenic cells to
predict the toxicity against normal cells referring to the previous
reports [15,18]. It was difficult to find an appropriate normal
control for comparative studies, and is therefore definitively
needed to study the toxicity of tenovin-6 (in combination with anti-
cancer drugs) in vivo, using animal xenograft models.
In conclusion, a sirtuin inhibitor, tenovin-6, showed a robust
antitumor effect against human gastric cancer cells. This was
independent of TP53 status and was induced via up-regulation of
DR5. Further study is needed to clarify the mechanism by which
tenovin-6 regulates DR5 expression. Tenovin-6 combined with
docetaxel and SN-38 had a small advantage for inhibition of
gastric cancer cell proliferation, which could provide a novel
strategy for the treatment of advanced gastric cancer.
Supporting Information
Figure S1 Relative intensity of the proteins’ expression
shown in Figure 3A. Semi-quantitation of Western blotting
densitometry involved normalization to b-actin levels.
(TIF)
Figure S2 Cytotoxic effects of chemotherapeutic drugs
in combination with tenovin-6. Cytotoxic effects of chemo-
therapeutic drugs including docetaxel, SN-38, cisplatin, and 5-FU,
and their enhancement of the effects of tenovin-6 in gastric cancer
cells with gastric cancer cells. The cells were cultured for 72 h with
the indicated concentrations of tenovin-6 and chemotherapeutic
drugs. A: Docetaxel (0.25 nM), B: SN-38 (1 nM), C: cisplatin (1 or
0.5 mM; NUGC-3 was treated with 0.5 mM cisplatin), and D: 5-
FU (0.25 mM) were given in combination with tenovin-6. The
statistical significance of differences between groups was evaluated
using Dunnett’s test. * p,0.01; ** p,0.05. DOC: docetaxel,
CDDP: cisplatin.
(TIF)
Figure S3 DR5 expressions after administration of
tenovin-6 with docetaxel or SN-38 in gastric cancer cells
(MKN-45 and KatoIII). Docetaxel, SN-38 and tenovin-6 were
administrated at a concentration of 0.25 nM, 1 nM and 2 mM.
Semi-quantitation of Western blotting densitometry involved
normalization to b-actin levels. DOC: docetaxel.
(TIF)
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